Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 3, 1999, Pages 145-152

  Weiss, Lola ^a   Reich, Shoshana ^a   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

B cell leukemia (BCL 1) cell therapy; BMT; GVL; r IL2

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; BONE MARROW CELL; CELL ACTIVATION; CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOTHERAPY; ISOGRAFT; LYMPH NODE CELL; LYMPHOCYTE; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; SPLEEN CELL; SPLEEN LYMPHOCYTE; SURVIVAL RATE; THYMOCYTE; TREATMENT OUTCOME;

ANIMALS; BONE MARROW TRANSPLANTATION; GRAFT VS LEUKEMIA EFFECT; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LEUKEMIA, B-CELL; LYMPHOCYTE TRANSFUSION; LYMPHOID TISSUE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 0032886520     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Weiden PL, Fluornoy N, Sanders JE et al, Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation (1981) 13: 248.
2. Sullivan KM, Weiden PL, Storb R et al, Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood (1989) 73: 1720.
3. Horowitz MM, Gale RP, Sondel PM et al, Graft-vs-leukemia reactions after bone marrow transplantation. Blood (1990) 75: 555.
4. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med (1988) 108: 806.
5. Agah R, Malloy B, Kerner M, Mazunder A, Generation and characterization of IL-2 activated bone-marrow cells as a potent graft vs tumor effector in transplantation. J Immunol (1989) 143: 3093.
6. Charak BS, Brynes RK, Ceroshen S et al, Bone marrow transplantation with interleukin-2 activated marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood (1990) 76: 2187.
7. Slavin S, Ackerstein A, Weiss L, Adoptive immunotherapy in conjunction with bone marrow transplantation - amplification of natural host defence mechanisms against cancer by recombinant IL2. Nat Immun Cell Growth Regul (1988) 7: 180.
8. Foa R, Guarini A, Gignetti et al, Cytokine gene therapy: a new strategy for the management of cancer patients. Nat Immun (1994) 13: 65.
9. Weiss L, Reich S, Slavin S, Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest (1992) 10: 19.
10. Slavin S, Ackerstein A, Kedar E, Weiss L, IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL2. Bone Marrow Transplant (1990) 6(Suppl 1): 86.
11. Cohen P, Vourka-Karussis U, Weiss L, Slavin S, Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor-and host-specific alloantigens. J Immunol (1993) 151: 4803.
12. Slavin S, Or R, Naparstek E et al, Eradication of minimal residual disease (MRD) following autologous (ABMT) and allogeneic bone marrow transplantation (BMT) by cytokine-mediated immunotherapy (CMI) and cell-mediated cytokine-activated immunotherapy (CCI) in experimental animals and man. Blood (1992) 80: 535a.
13. Slavin S, Naparstek E, Nagler A et al, Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood (1996) 87: 2195.
14. Slavin S, Strober S, Spontaneous murine B-cell leukemia. Nature 1978; 272: 624.
15. Slavin S, Weiss L, Morecki S et al, Ultrastructural, cell membrane and cytogenetic characteristics of B-cell leukemia (BCL1), a murine model of chronic lymphocytic leukemia. Cancer Res (1981) 41: 4162.
16. Warnke RA, Slavin S, Coffman RL et al, The pathology and homing of a transplantable murine B cell leukemia (BCL1). J Immunol (1979) 123: 118.
17. Slavin S, Morecki S, Weiss L, The role of the spleen in tumor growth kinetics of the murine B cell leukemia (BCL1). J Immunol (1980) 124: 586.
18. Rajaram N, Revati J, Tatake RJ et al, Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia. Cancer Immunol Immunother (1990) 31: 44.
19. Rosenberg SA, Zotze MT, Muul LM et al, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 313: 1484.
20. Weiss L, Morecki S, Vitetta ES, Slavin S, Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation. J Immunol (1983) 130: 2452.
21. Ackerstein A, Kedar E, Slavin S, Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. Blood (1991) 78: 1212.
22. Barrett AJ, Jlang YZ, Kanfer EJ, Gordon AA, T cell clones with cytotoxicity to CML cells exert leukaemia-specific cytokine-mediated suppression of chronic myeloid leukaemia (CML) CFU-GM. Exp Hematol (1992) 20: 723.
23. BCR-ABL protein. Proc Natl Acad Sci USA (1992) 89: 1468.
24. Van Lochem E, De Gast B, Goulmy E, In vitro separation of host specific graft-versus-host and graft-versus leukemia cytotoxic-T-cell activities. Bone Marrow Transplant (1992) 10: 181.
25. Schwarer AP, Jiang YZ, Deacock S, Brookes PA, Comparison of helper and cytotoxic anti-recipient T cell frequencies in unrelated bone marrow transplantation. Transplantation (1994) 58: 1198.
26. Stark J, Weiss L, Slavin S, Radiosensitivity and responsiveness to recombinant rIL-2 of effector cells of graft vs host disease (GVHD) and mixed lymphocyte reaction (MLR) in mice. Isr J Med Sci (1992) 28: 767.
27. Bishara A, Amar A, Brautbar C et al, The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT). Exp Hematol (1995) 23: 16567.
28. Slavin S, Ackerstein A, Kedar E et al, Induction of cell-mediated IL2-activated anti-tumor responses in conjunction with autologous and allogeneic bone marrow transplantation. Transplant Proc (1991) 23: 802.
29. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S, Enhancement of graft versus leukemia effect (GVL) with recombinant human interleukin 2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol (1995) 23: 196.
30. Slavin S, Naparstek E, Nagler A et al, Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol (1995) 23: 1553.
31. Weiss L, Nusair S, Reich S et al, Induction of graft vs leukemia effects by cell-mediated lymphokine activated immunotherapy after syngeneic BMT in murine B-cell leukemia. Cancer Immunol Immunother (1996) 43: 103.
32. Or R, Nagler A, Ackerstein A et al, Allogeneic cell-mediated cytokine-activated immunotherapy of non-Hodgkin lymphoma for eradication of minimal residual disease in conjunction with autologous bone marrow transplantation (ABMT). Blood (1993) 82(Suppl 1): 171a.
33. Slavin S, Naparstek E, Nagler A et al, Cell mediated immunotherapy (CMI) for the treatment of malignant hematological diseases in conjunction with autologous bone marrow transplantation (ABMT). Blood (1993) 82(Suppl 1): 292a.